Anthony Elias, MD

Professor, Medicine-Medical Oncology


FacultyPhoto
Medical School
  • MD, New York University School of Medicine (1980)
Undergraduate School
  • BA, Princeton University (NJ) (1976)
Internship
  • Johns Hopkins University School of Medicine Program (1981)
Residency
  • Johns Hopkins University School of Medicine Program, Internal Medicine (1983)
Fellowships
  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute Program, Medical Oncology (1987)
Languages
English
Department
Medicine-Medical Oncology

Recognitions

  • Top Doctor in Oncology, Castle Connolly (2017)
  • Top Doctor in Newsweek, Castle Connolly (2015)
  • Foundations in Medicine Golden Stethoscope Award for Patient/Physician Communication, University of Colorado School of Medicine (2014)
  • Best Doctor for Executives, ColoradoBiz Magazine (2012)
    Named Best Doctor for Oncology and Hematology, Breast Cancer, Lung Cancer, Stem Cell Transplant and Sarcomas.
  • Top Doctor, US News & World Report (2011)
  • Member, AOA (1980)

Research Interests

Clinical trials

Publications

  • Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 Feb 16;30(4):729-740. PubMed PMID: 38109213
  • O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R Jr, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024 Aug 30;12(8). PubMed PMID: 39214650
  • Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3737-3747. PubMed PMID: 39277672
  • Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER /Her2- breast cancer. NPJ Breast Cancer. 2024 Oct 6;10(1):88. PubMed PMID: 39368973
  • Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3728-3736. PubMed PMID: 39277671

Professional Memberships

  • ASCO, Member
  • SWOG, Member
  • AACR, Member
  • SARC, Member

Practice Locations

UCHealth Diane O'Connor Thompson Breast Center - Anschutz
1635 Aurora Ct
3rd Floor
Aurora, CO 80045
720-848-1030

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (1983)
  • Medical Oncology, Board Certification (1985)
Conditions & Treatments
  • Cancers - Bone Cancer
  • Cancers - Breast Cancer
  • Cancers - Sarcoma
  • Cancers
Clinical Interests
Breast Cancer treatment Sarcoma treatment

Personal Interests
Violinist, chamber musician in spare time

Volunteer Activities
Member of the Board The Children's Treehouse Foundation